Large-scale AIDS vaccine trial dropped

updated 12:46 p.m. ET July 18, 2008

WASHINGTON - Plans for a large-scale trial of a potential AIDS vaccine are being dropped in favor of a smaller, more focused study, the National Institutes of Health said.

The trial of the vaccine, developed by the Vaccine Research Center at the National Institute of Allergy and Infectious Disease, had been planned to include 2,400 men in the United States in a study called PAVE 100.

However, the agency said Thursday that it has decided that the vaccine did not warrant a trial of this size and scope. Instead NIAID said it will plan a smaller, more focused clinical trial designed to see whether the product has a significant effect on the amount of virus in a person's blood.

If an effect is found, then additional studies, or an expansion of the study could be carried out.

NIAID said it acted after reviewing the results of the STEP trial, a study of another vaccine that was halted last fall after reports of an increased number of infections among volunteers taking part in the test.

The agency said it still considers its vaccine scientifically intriguing and sufficiently different from other vaccines to proceed with the smaller trial.

Don't miss this on msnbc.com Health   Alzheimer's offspring confront their own risk Never to part: Devoted couples share life, death After breast cancer, weighty battle ahead Body Odd: What's in a wink? It's no secret! Why we love gossip

MORE FROM AIDS

AIDS Section Front

AIDS vaccine focus shifts after disappointments Circumcision may not reduce gay male HIV risk CDC: 1.1 million Americans have AIDS virus AIDS virus decades older than thought AIDS epidemic hits men hard Herpes drug may help control AIDS virus Big risks for rising number of child brides New HIV infections in NYC 3 times U.S. rate ‘Elite’ woman may hold key to AIDS vaccine AIDS prevention gives short shrift to gays AIDS Section Front   Add AIDS headlines to your news reader: